Metabolomics—often referred to as the youngest of the omics—provides key insight into phenotype. However, bulk metabolomics requires the homogenization of the sample and is thus unable to discern metabolic differences at a cellular level.
Metabolomics—often referred to as the youngest of the omics—provides key insight into phenotype. However, bulk metabolomics requires the homogenization of the sample and is thus unable to discern metabolic differences at a cellular level.
TetraScience, the R&D Data Cloud company, announced today that Paradigm4, an integrated scientific data analytics company, has joined the Tetra Partner Network (TPN) so that pharmaceutical customers can accelerate research decision-making using Tetra Data as a foundation for analytical computing.
The idea of precision medicine – delivering the right drug treatment to the right patient at the right time and at the right dose – underpins current thinking in pharma R&D. by Zach Pitluk
More sensitive technology spurs proteomic and metabolomic biomarker identification, clinical use. (Complete article on page 21)